Blogs

Growth of pharma industry and contribution of generics

  • Global pharma growth and trends
  • How are generic drugs driving the growth in pharma globally?
  • Key contributors to the ongoing expansion of generic pharma

 

Global pharmaceutical spending is expected to reach USD 1.5 trillion by 2021 with CAGR of 4 to 7% in the next 5 years according to the report released by QuintilesIMS Institute-Outlook for Global Medicines through 2021. Increase in the lifestyle-related diseases and chronic ailments, an ageing population, a launch of innovative and speciality drugs, greater consumer information and empowerment, improved accessibility to healthcare and medical infrastructure, expansion of emerging market, demographic trends and increasing per capita income are the major drivers for this global demand. There is an estimated increase in pharma spending of USD 367 billion from 2016 to 2021 with a CAGR of 4-7%, as stated above. The introduction of new innovative products, especially in oncology, autoimmune and diabetes treatments in the developed markets and enhanced use of branded generics in pharmerging* markets will be the two major contributors for the incremental growth of the pharma sector apart from the use of low-priced alternatives (after a loss of exclusivity), improved access of modern medicines and increased healthcare awareness. 

*Pharmerging market includes countries with >USD 1 billion absolute spending growth over 2014-2018 and the GDP per capita <USD 30 thousand at purchasing power parity. This includes China, Brazil, Russia, India, Algeria, Argentina, Bangladesh, Chile, Colombia, Egypt, Indonesia, Kazakhstan, Mexico, Nigeria, Pakistan, Philippines, Poland, S. Africa, Saudi Arabia, Turkey and Vietnam

Although original branded medicines have the largest share in the pharmaceutical industry and are projected to have a 56% share in the global spending (2021). The generic’s share, which includes both the branded and non-branded generic medicines is also growing at a much faster pace. Its share in the global medicine spending is anticipated to rise from 27% (2013) to 34% (2021) with a CAGR of 8.3% as compared to the total spending, which is likely to grow at a CAGR of 5.2%. According to the QuintilesIMS, the global spending on generic medicines will probably reach USD 495-505 billion by 2021.

  

Generic pharma driving the global pharma growth

The US Food and Drug Administration (FDA) has defined generic medicine as a drug product that is comparable to a brand/reference listed drug product in quality, performance, intended use, the form of dosage, strength and route of administration. Hence, a generic medicine work in a similar way, provides identical clinical benefits of a branded version and has same risks of an original branded medicine.

A new drug is typically protected by patents that provide a certain period of exclusivity in the market. Hence, during this phase pharmaceutical companies do not face a competition from generic drugs. These generic drugs can only enter the market after an expiration of the branded drug’s patent, which usually lasts for 20 years. There are two types of generic drugs; pure generic which is ‘equivalent’ to the original brand in every aspect and branded generic, that is ‘bioequivalent’ to the original brand product, but this is presently marketed under another company’s brand name. The branded generic products are either novel dosage form of off-patent product or copied version of an off-patent product with a trade name.

According to the QuintilesIMS, a growing use of cheap alternative generic in pharmerging markets is a leading contributor to the rise of the market for generic drugs. This is both in terms of the growth and the share. Moreover, branded generics in emerging markets are also likely to contribute as a key driver to growth for the overall generic market.

Generic drugs, which are estimated to have 34% share in the global pharma spending and 26% share in the developed market, will probably have more than half of the share in the pharmerging markets by 2021. Growing at a CAGR of 9-12% (2017-21), generic pharma market has its own drivers contributing to its growth:

  • Patent cliff: a key driver for boosting generic drug growth. The loss of patent protection by branded drugs is known as patent cliff. This opens the door for generic’s entry into the market. According to QuintilesIMS, a patent expiration will impact USD ~170 billion (one-third greater than the past 5 years) pharma market in the developed countries (2016-21).
  • Lower pricing: according to an estimate after the first 6 months of a patent’s expiry, the average price of a generic drug is normally 60-70% lower than the original brand drug. This further reduces to 80-90% following 24 months of availability of generic medicine. Unlike the original drug producer, which invests a huge sum of money in the research and development (as per the CSDD [Tufts Center for the Study of Drug Development] average USD ~2.6 billion for a new drug, which gained market approval) over 10 years plus, the generic drug producers in contrast are able to offer copies of the original drug at a far cheaper rate as the drug has already been formulated and approved. The first generic drug mover also gets a short market exclusivity (180 days), the original brand name drug loses ~90% or more of its market share in a shorter span of time due to a deluge of generic drug offering in the market.
  • Increasing medicine volume: global medicine volumes have increased to ~4 trillion doses (2016) from ~2.5 trillion doses (2006), with nearly 75% growth from the pharmerging market. In the US, generic drugs account for ~90% of the prescription, this is anticipated to rise ~92% by 2021. Similarly, in the contemporary pharmerging markets, on an average 90% of prescriptions account for generic medicines.
  • Supportive government policies: in order to expand the healthcare provisions and enhance its reach. Growth in economies of emerging markets due to rising per capita income empowered these for advancing healthcare by increasing healthcare awareness and medical penetration. The demand for generic medicines is quite apparent as governments, as well as consumers, pursue avenues to reduce their healthcare costs.

Furthermore, according to the USFDA (U.S. Food and Drug Administration), a record 763 generic drugs were approved in 2017 and 174 tentative approvals were given in the same year. The total fillings of ANDA (Abbreviated New Drug Application) for generic drugs also surged to 1,292 applications in 2017 from 852 applications in 2016.

In the US, which is a leader in the global pharma market, the legislative enactments encouraged more generics. There was a passage of two milestone acts; Obama Care Act (PPACA) in 2010 and Generic Drugs User Fee Amendments (GDUFA) in 2012. These invigorated generic drug use while strengthening the USFDA to expedite approvals without a compromise on quality. PPACA made a mandatory program to bring ~50 million citizens under various government health insurance schemes and maximised use of generics in order to avail optimum benefits under these schemes. GDUFA strengthened resources of USFDA by charging generic aspirants for ANDA/DMF (Drug Master File) and plant approval over and above a normal fee. Thus, USFDA was able to expedite approvals, inspection processes and reduced backlogs on filings with greater availability of resources. In addition, Hatch-Waxman Act expedited and streamlined generic drug approvals and patent related litigations. 

The branded drugs lost USD 91.1 billion (2012-16) due to patent expiry in the US pharma space. A loss of exclusivity is expected to have 58% greater impact in the next 5 years as compared to the foregone 5 years according to the QuintilesIMS, this will have a bearing of roughly USD 143.5 billion (2017-21). These developments have created an immense opportunity for generic players. According to the IMS Health Institute, generic drugs saved the US healthcare system of USD 1.67 trillion (2007-16).

Moreover, China, which is the second largest pharma market globally and is also a leader in the pharmerging market is projected to have a spending of USD 150-180 billion by 2021 on medicines. The nation has delayed its issuance of updated National Reimbursement Drug list since 2009, which provides reimbursed access to medicines and thus, limiting patient access to new medicines as these are not widely available in China. However, transforming government priorities and policies have already affected spending on drug growth during 2015-16, this was followed by a series of price cuts in China. Thus, all this slowed down the estimated growth in pharma spending to 5-8% CAGR (2021) from 12.5% CAGR (2011-16).

Similarly, the Japanese government has been advocating the use of low-cost generics in order to control the overall pharmaceutical spending. This was done through the implementation of regulations and a series of reforms to encourage generic use in the past few years and target 80% of the generic market by 2020. The volume share for generics in Japanese pharma space has increased to 65.1% (2017) from ~40% ([2011] Source: Statista).

Therefore, it can be stated that with the ageing population, an increasing demand for affordable healthcare and governmental focus on cost-cutting, there exist thriving opportunities for generics all across the globe. Each region has its specific requirements, thus distinct opportunities reflect a region-centric demography. While North America leads in the pharma market space, pharmerging countries will have the highest volume of consumption and penetration of affordable generic drugs. The generic market is continually consolidating through several M&A activities such as Teva’s acquisition of Allergan, besides venturing into super generic opportunities in order to overcome low margins. The availability of inexpensive, safe and effective alternatives for medicines in form of generic balance on cost will provide improved healthcare at a reasonable price. 

Your Rating

Baidu’s Apollo, the underdog of autonomous driving platform

Overview of the autonomous vehicle sector in the global automobile industry Search giant Baidu’s entry into the autonomous driving space Baidu’s approach in becoming a front-runner...

An analysis of Malaysian rubber glove industry

How big is the international rubber gloves market? Reasons behind the healthy and steady growth Malaysia’s role in the industry Why are companies struggling for stable...

Can lithium-ion anode demand for needle coke reduce availability for electrode players?

What is needle coke? Uses of needle coke Lithium-ion battery manufacturers demand needle coke   Needle coke? Needle coke is a specialised form of petroleum coke...

Tire manufacturing industry, analysing the cost and margin trends

The global market for tire manufacturing stands at $180 billion. Michelin anticipates the long-term demand to rise at the rate of 5 to 10% a year in developing markets and 1 to 2% a year in mature...

Failure of Amazon in China, an analysis

E-commerce market in China Online consumer product retailers in China Performance of Amazon in China   Amazon is a global e-commerce player selling a wide...

US commercial space launch industry at a tipping point with the rising of small rocket players

The commercial space launch industry witnessing a transition towards Low Earth Orbit (LEO) satellite launches Emergence of numerous small rocket start-ups Increased consumer...

Sri Lankan economic and political crisis

Sri Lanka’s latest political crisis, who governs the nation? Poor economic indicators adding to the nation’s woes   Sri Lanka is currently embroiled in a political crisis,...

Rice industry outlook 2018

Major rice producers and consumers Global rice trade Factors dominating the trade   Rice is the 3 rd largest produced agricultural commodity in the world, after...

Used car market in India, online start-ups organising the sector

Per capita car ownership is low as compared to other developed nations and the global average Used cars were not a preferred means of ownership due to lack of trust among buyers and...

Unnoticed growth of the media and entertainment industry in India

Overall industry brief Growth of the M&E industry and its segments Major supporting elements of this growth   Media and Entertainment (M&E) is a very wide industry...

Impact of the legalisation of cannabis on the consumer goods sector in the US

Cannabis is perceived to be the healthiest intoxicating compound in the world Consumer preference is shifting from smoking to drinking/eating cannabis Cannabis or marijuana as it...

Rapidly growing Indian online food delivery industry and its unrealised profits

Evolution of online food delivery industry in India Geographical penetration and scope for expansion Key players and their zeal to balance revenue and costs   Online...

US government pulls out of the global postal policy

What is the UPU ( Universal Postal Union )? Why did the US pull out of the UPU? Impact on the Chinese retailers, currently the major beneficiary of the UPU   ...

Is the radio broadcasting industry in the U.S. dying? An analysis

Radio, the most powerful medium of reach in the U.S. Why the industry is moving at a slow pace? Radio’s health is still sound, will it continue in the long-term?   ...

Can PepsiCo turnaround the performance of its North American beverage segment?

What led to the consistent decline of PepsiCo’s trademark drinks in the last few years? Can the recent improvement in top-line numbers for PepsiCo’s beverage segment be maintained in...

Disruption in the candy market

Global confectionery market Changes in the market dynamics of the candy industry The future of candies   ‘Candy’ is an all-time favourite among most throughout the...

Battle for the textile and apparel industry in Southeast Asia

The reasons for China’s decreasing presence in the industry Initiatives by the governments in Southeast Asia to boost the textile trade Vietnam and Bangladesh’s quest to conquer...

Rise of Ant Financial, will the success story continue?

What is Ant Financial? Journey to become king of unicorn Will regulatory curbs hinder its success journey?    Ant Financial, an affiliate and integral part...

SAP’s acquisition of Qualtrics, a costly affair or a strategic move?

History and evolution of SAP and ERP. Will experience measurement add value to SAP ERP?   On November 12, 2018 ERP software giant SAP announced an $8 billion acquisition...

Indian wood panel industry, growth drivers and present trends

Current market scenario in the Indian plywood industry Growth in the housing sector and rapid urbanisation to provide the boost GST rationalization to reduce price difference...